RxDoctor Payments DataLook up a doctor →

Patrick Cambier, MD

Interventional Cardiology · Trinity, FLNPI 1508828591

Payments from drug & device makers

$1,059,959in general payments, 2019–2025

Across 1,276 payments — averaging $830.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$331K
  • Novo Nordisk$301K
  • Janssen Research & Development, LLC$153K
  • Merck$101K
  • E.r. Squibb & Sons, L.L.C.$77K
  • Pfizer$61K
  • plus $37K from 33 others

What the payments were for

  • Consulting fees$74,5558%
  • Speaking & faculty fees$718,16280%
  • Travel & lodging$60,4347%
  • Food & beverage$25,3063%
  • Education$2850%
  • Other$21,9172%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,059,959 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$334,993
Medicare patients
1,072
Services billed
3,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban516$530,171
FarxigaDapagliflozin Propanediol377$377,313
EntrestoSacubitril/Valsartan329$305,009
OzempicSemaglutide177$189,868
Repatha SureclickEvolocumab188$138,755
XareltoRivaroxaban64$71,212
BrilintaTicagrelor95$69,212
MultaqDronedarone Hcl49$55,605
JardianceEmpagliflozin37$45,917
VerquvoVericiguat25$16,707
Repatha SyringeEvolocumab21$15,937
Candesartan Cilexetil189$13,493
Rosuvastatin Calcium873$10,200
Metoprolol Succinate724$9,121
VascepaIcosapent Ethyl22$7,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$60,996$530,171516 claims
AstraZenecaFarxiga, Brilinta$330,665$446,526472 claims
NovartisEntresto$547$305,009329 claims
Novo NordiskOzempic$300,536$189,868177 claims
Johnson & JohnsonXarelto$319$71,21264 claims
Sanofi-aventis U.S. LLCMultaq$223$55,60549 claims
Boehringer IngelheimJardiance$180$45,91737 claims
MerckVerquvo$100,989$16,70725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Trinity

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →